Table 4.
Comparison of clinicopathological features to co-expression of CD176 and CD44†
| CD176 | CD44 | CD176±CD44± | ||||
|---|---|---|---|---|---|---|
| Tumour and clinicopathological features | 5–30% | >30% | 5–30% | >30% | 5–15% | >15% |
| Lung carcinoma (21 cases) | ||||||
| Histological type | ||||||
| ACA | 5/13 (38) | 4/13 (31) | 0/13 | 13/13 (100) | 6/13 (46) | 5/13 (38) |
| SCC | 4/8 (50) | 3/8 (38) | 0/8 | 8/8 (100) | 3/8 (38) | 2/8 (25) |
| TNM stage | ||||||
| I + II | 6/12 (50) | 6/12 (50)* | 0/12 | 12/12 (100) | 5/12 (42) | 5/12 (42) |
| III + IV | 3/9 (30) | 1/9 (11)* | 0/9 | 9/9 (100) | 3/9 (33) | 2/9 (22) |
| Differentiation | ||||||
| Poor | 5/6 (83) | 5/6 (83)* | 0/6 | 6/6 (100) | 4/6 (67) | 3/6 (50) |
| Well or Moderate | 4/15 (27) | 2/15 (13)* | 0/15 | 6/15 (100) | 4/15 (27) | 5/15 (34) |
| Breast carcinoma (15 cases) | ||||||
| Histological type | ||||||
| IC | 8/10 (80) | 1/10 (10) | 0/10 | 10/10 (100) | 6/10 (60) | 2/10 (20) |
| NIC | 4/5 (80) | 0/5 | 1/5 (20) | 4/5 (80) | 3/5 (60) | 0/5 |
| TNM stage | ||||||
| I + II | 5/5 (100) | 1/5 (20) | 1/5 (20) | 4/5 (80) | 4/5 (80) | 1/5 (20) |
| III + IV | 7/10 (70) | 0/10 | 0/10 | 10/10 (100) | 5/10 (50) | 1/10 (10) |
| Differentiation | ||||||
| Poor | 5/6 (83) | 1/6 (17) | 1/6 (17) | 5/6 (83) | 4/6 (67) | 1/6 (17) |
| Well or Moderate | 7/9 (78) | 0/9 | 0/9 | 9/9 (100) | 5/9 (56) | 1/9 (11) |
| HCC (21 cases) | ||||||
| TNM stage | ||||||
| I + II | 3/11 (27) | 3/11 (27)* | 0/11 | 11/11 (100) | 3/11 (27) | 5/11 (45) |
| III + IV | 4/10 (40) | 1/10 (10)* | 0/10 | 10/10 (100) | 3/10 (30) | 2/10 (20) |
| Differentiation | ||||||
| Poor | 3/5 (60) | 2/5 (40) | 0/5 | 5/5 (100) | 2/5 (40) | 2/5 (40) |
| Well or moderate | 4/16 (66) | 2/16 (33) | 0/16 | 16/16 (100) | 3/16 (19) | 5/16 (31) |
†
Values are no. of cases applicable / total no. of cases examined (with per cent in parentheses). The statistical differences were compared using the Fisher's exact test (two-tailed).
*
P < 0.05.
ACA, adenocarcinoma; SCC, squamous cell carcinoma; IC, infiltrative carcinoma; NIC, non-infiltrative carcinoma; HCC, hepatocellular carcinoma.